Customer Segmentation

A top-10 biopharma wanted to assess how the biomarker testing and treatment landscape would change, and the potential impact on the use of their drug, in response to a recent approval of a new competing cancer therapy approved in earlier lines of treatment

DeciBio conducted financial projections, valuation, and assisted with messaging to aid client's public listing to NASDAQ

A large pharma new to precision oncology wanted to understand the processes and requirements to ensure that their novel CDx was included into diagnostic guidelines globally

A leader in research tools and clinical diagnostic development asked us to evaluate the opportunity for an ultrasensitive detection platform in methylation analysis

A diagnostics company requested DeciBio to help an advisory board (ad board) to understand how to position its relatively new somatic oncology genomics profiling product in an already competitive market

A leading diagnostic company wanted an assessment of the future market landscape for low-throughput (LT) molecular diagnostic (MDx) testing to develop a long-term platform strategy to address the future needs of this market